I. INTRODUCTION
When cells are exposed to ionizing radiation, they release poisons which result in death, mutation, chromosomal aberrations or long term genomic instability in neighboring, unirradiated cells (Mothersill and Seymour 2001; Mothersill and Seymour 2004; Lyng et al 2002; Lorimore and Wright 2003; Morgan 2003; Little 2003) . These consequences, known as radiation induced biological bystander effects (RIBBE), may contribute significantly to the effectiveness of radiotherapy by sterilising malignant cells which have not been directly irradiated.
In recent years, targeted radionuclide treatment of cancer has developed as a novel and advantageous approach to radiation therapy. The basic idea is to deliver higher doses of radiation to tumor than to normal cells by means of radionuclides chemically conjugated to tumor-seeking targeting agents such as meta-iodobenzylguanidine (MIBG). By virtue of its structural similarity to noradrenaline (Wieland et al 1980) , MIBG is selectively accumulated via the noradrenaline transporter (NAT) (Jacques et al 1984) which is expressed on the surfaces of cells comprising tumors of neural crest origin, for example neuroblastoma and phaeochromocytoma. Radiolabelled forms of this drug are used for scintigraphic assessment and treatment of such tumors (Simpson and Gaze 1998; Klingebiel et al 1998; Hoefnagel 1999; Rose et al 2003) . NAT expression is predictive for MIBG uptake capacity (Mairs et al 1994) and quantification of NAT mRNA could be used for the selection of patients for MIBG therapy (Carlin et al 2003) .
It may be possible to compensate for heterogeneity of uptake of radiopharmaceutical, resulting in underdosing of some tumor regions, by the selection of radionuclides whose decay particles have long path lengths, enabling cross-fire irradiation of surrounding untargeted cells. However, even with long range radionuclides, because their emissions are of low LET, sub-populations of tumor cells will receive less than a sterilizing dose. Then again, emerging evidence suggests that radioactive emission from targeted cells is not the only bystander effect operating in radionuclide treatment of cancer. It is becoming clear that radiation-induced biological bystander effects (RIBBE) deriving from the cellular processing of the physical radiation insult, which need not interact directly with DNA, may play an important part in the overall efficacy of radionuclide targeting. RIBBE predominate at low radiation dose and low dose rate (Carlsson et al 2003) both of which are features of targeted radionuclide treatment of cancer. Therefore bystander effects induced by radiopharmaceuticals may play a disproportionate role in the efficacy, and understanding their nature should enable the refinement of radiotherapy. Most investigations of bystander effects have involved external beam γ-irradiators and microbeams. However, in recent years important studies have been conducted of RIBBE after intracellular concentration of radiolabelled drugs. Bishayee et al (2001) Here we describe bystander responses following the uptake of radiohaloanalogues of MIBG by NAT gene-transfected tumor cell lines. Our results provide further insight into the dependence of targeted radiotherapy on RIBBE and the influence of radiation quality.
II. TRANSFECTANT MOSAIC SPHEROIDS: A NEW MODEL FOR EVALUATION OF TUMOR CELL KILLING IN TARGETED RADIOTHERAPY AND GENE THERAPY
An attractive characteristic of therapeutic strategies which combine gene manipulation with the administration of radiopharmaceuticals is cross-fire irradiation of non-transfected cells. We assessed the usefulness of this effect using our recently developed mosaic spheroid model (Boyd and Mairs 2004 ) composed of mixtures of transfected and untransfected cells (Boyd et al 2002) (Figure 1 ). This allowed our evaluation of the minimum percentage of transfection required to achieve cure of different sizes of metastases. For example: modest radioactivity concentrations (20 kBq/ml) of [
211 At]MABG induced the complete sterilisation of 250μm diameter mosaic spheroids composed of only 5% NAT gene transfectants (Figure 2 ). Because the path length of 211 At α-particles is only 55 to 70 μm, cross-fire irradiation from targeted to untargeted cells would be considerably less extensive than that from a β-emitter such as 131 I. Therefore this observation suggests that bystander effects, over and above cross-fire irradiation, are operating in α-particle targeted therapy.
These studies indicate the potential for bystander-mediated cell kill and improved clinical efficacy of tumor targeting when only a small proportion of the tumor mass expresses the radiotherapeutic molecular target, in this case, introduced via gene modification. Moreover, RIBBE could compensate for the low levels of gene delivery currently achievable in vivo in cancer gene therapy strategies when married with targeted radionuclide therapy. Rational selection of radiohaloconjugates of MIBG will enable the enhancement of cross-fire kill to maximize neuroblastoma cell kill.
III. MEDIA TRANSFER METHOD FOR ASSESSMENT OF RIBBE
Our procedure for determining bystander responses in vitro employs an adaptation of the media transfer system developed by Mothersill and Seymour (1997) to compare the induction of bystander effects by external beam γ-radiation with those generated by MIBG labelled with radionuclides emitting β-particles, α-particles, or Auger electrons (Boyd et al 2006) . The cells used in these experiments were transfected with the NAT gene to facilitate the active uptake of radiolabeled MIBG. Similarly treated control cells were untransfected and hence incapable of concentration of the radiopharmaceutical. This allowed our determination of the requirement for intracellular accumulation of radionuclide for induction of RIBBE.
For investigation of RIBBE following γ-irradiation, donor cells were directly irradiated and their medium was transferred to recipient cells which were not directly irradiated. Separate cultures (termed "direct") were directly irradiated and their medium was not removed. Consequently the direct cells experienced the physical and biological effects of the radiation treatment. For the evaluation of RIBBE in radiopharmaceutical-treated cells, it was necessary to control for killing of recipient cells due to the transfer of radiopharmaceutical effluxed from donor cells. To cultures, designated activity controls, was administered radiopharmaceutical activity equivalent to that which had leaked from donor cultures and would have been transferred to recipient cells. 24 h after these manipulations, cell kill was determined by clonogenic assay (Figure 3 ).
IV. RIBBE INDUCED BY γ γ-IRRADIATION AND TARGETED RADIOPHAR-MACEUTICALS
We observed that exposure of two human tumor cell lines-UVW glioma and EJ138 bladder carcinoma-to media derived from external beam irradiated cells produced a dose-dependent reduction in survival fraction in the dose range 0 to 2 Gy, followed by a plateau in clonogenic cell kill at levels greater than 2 Gy (Figure 4) . Similarly, other reports of media transfer experiments, following treatment with γ-rays or soft x-rays, have indicated that the dose-response in bystander cells reached a plateau at low doses (Mothersill and Seymour 1997; Seymour and Mothersill 2000; Belyakov et al 2001) .
In contrast, no such plateau with respect to clonogenic cell kill was evident in recipients of medium from NAT-expressing cells incubated with [
211 At]MABG, RIBBE became progressively weaker ( Figure 6 ). The Ushaped survival curves associated with intracellularly concentrated high-LET emitters suggest that, after intracellular bombardment, the RIBBEgenerating apparatus is inhibited above a threshold radiation dose. The RIBBE elicited by the pre-nadir activity range of these high LET targeted radionuclides resulted in a magnitude of cell kill similar to that caused by direct irradiation, indicating that bystander effects may be significant contributors to the cytotoxicity of [ 123 I]MIBG and [ 211 At]MABG at low activity concentrations. It will be important to the development of tumor targeting by [
125 I]-and [ 211 At]-labeled compounds to determine differences in the nature of toxins generated at low (pre-nadir) and high (postnadir) radioactivity concentrations.
Significantly, neither direct nor indirect kill was observed at any activity concentration in cultures of cells which did not express the NAT and were incapable of active uptake of MIBG. Thus, these RIBBE effects were not related to decays of unbound radiopharmaceutical present in the media. These findings suggest that potent toxins are generated specifically by cells which concentrate targeted radionuclides. Furthermore, a comparison of the dose dependence of these effects with those observed after exposure to γ-rays suggests that RIBBE effects from targeted radiotherapeutics may be distinct from those elicited by conventional external beam radiotherapy.
V. CONCLUSION
The successful application of targeted radionuclide cancer therapy is critically dependent on the delivery of cytotoxic doses of radiation to the vast majority of the malignant cell population. Achieving this goal can be confounded by multiple factors, including variations in target molecule expression and tumor hemodynamic parameters, that can lead to heterogeneity in radiopharmaceutical delivery, retention or binding. However, it has been widely appreciated that cells not accumulating the labelled molecule can be killed as a result of being hit by radiation emitted from neighboring cells. Consideration of this process, known as the (physical) bystander effect, has played an important role in the design of radiotherapeutic strategies, for example, the selection of long range β-particle emitters in situations where heterogeneous radiopharmaceutical delivery is anticipated.
A second type of bystander effect that could have important implications for targeted radionuclide therapy is the radiation induced biological bystander effect (RIBBE), which results in the killing of cells not directly exposed to radiation. The mechanisms involved are as yet undefined. However, studies using γ-ray and α-particle beams have provided some insight into possible factors. These include oxidative stress leading to increased radical formation (Lehnert and Goodwin 1997; Narayanan et al 1997) nitric oxide release (Matsumoto et al 2001; Shao et al 2002) cytokine release (Iyer and Lehnert 2000) and gap junctional intracellular communication (Azzam et al 2001) . RIBBE resultant from targeted radionuclides has largely been unexplored and the effects of radiation quality remain unknown (Mairs and Boyd 2005) .
Elucidation of the pathways involved in RIBBE generation by radionuclides could indicate ways of manipulating RIBBE production to reduce toxicity to normal tissues which are inadvertently irradiated during the course of a targeted radiotherapy regime. Careful choice of radionuclides and dose administered in clinical scenarios for targeted radionuclide therapy of tumors which naturally accumulate targeted radionuclides or have been genetically manipulated to do so, will allow factors such as inefficient gene transfer and heterogeneous uptake to be compensated for, thus optimising the cell kill potential of this therapeutic scheme.
Whatever the mechanism, RIBBE could be important not only in relation to radiation protection and safety but also with respect to the therapeutic use of ionizing radiation. Exploitation of RIBBE could be especially relevant to the efficacy of targeted radiotherapy because this treat-ment is limited by heterogeneous uptake of radionuclides by tumors. Freely diffusible toxic bystander signals could overcome the inefficiency of tumor control due to non-uniform distribution of radiation dose.
We seek now to investigate the nature of RIBBE signals generated by radiopharmaceuticals localized to different sub-cellular regions. The efficiency of this mode of kill in tumor and normal cells and its possible dependence on genetic background and tumor microenvironment must also be assessed. From a practical perspective, the identification of RIBBE factors will stimulate the design of strategies to maximize damage to tumor cells while minimizing damage to normal cells.
